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Abstract   
Carbapenems are therapeutic choice against infections caused by Gram-negative bacilli including strains of 
Pseudomonas aeruginosa. New Delhi metallo-β-lactamase (NDM-1) is a novel metallo-β-lactamase (MBL).That 
confers resistance to all β-lactamases. Sporadic cases of NDM-1 positive strains have been reported from 
different countries. The aim of this study was to determine the possibility of existence of NDM-1 gene among P. 
aeruginosa isolates collected from Najaf hospitals. Thirty-six carbapenem resistant P. aeruginosa isolates were 
collected from various clinical samples. The susceptibility to different antibiotics was evaluated by disk diffusion 
method, MICs of imipenem and meropenem were determined. The blaNDM was detected by PCR. All isolate 
were multidrug resistance. Two isolates were harbored blaNDM genes. The MICs of isolates to imipenem and 
meropenem were 4-128 µg/mL and 4-256 µg/mL, respectively. The study  concluded that production of MBL 
enzymes presents an emerging threat of carbapenem resistance among P. aeruginosa in Najaf province. This is 
the first report of NDM β-lactamase producing P. aeruginosa in Iraq. 
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Introduction 
Pseudomonas aeruginosa is an important cause of nosocomial infections and has been associated with a wide 
variety of illnesses in hospitalized patients, especially patients in the intensive care units (Brooks et al., 
2007).The clinical strains of P. aeruginosa are usually multidrug resistant to aminoglycosides, fluoroquinolones, 
ureidopenicillins and third generation cephalosporins. In cases of resistance to β-lactams caused by extended 
spectrum β-lactamases and AmpC enzyme, carbapenems are often used as the last resort against infections. 
However, carbapenem- hydrolyzing- β-lactamases of molecular class A, B and D have emerged over the last 
decade (Strateva &Yordanov 2009).  
The emerging NDM-1, an acquired class B carbapenemase that was first clinically detected in a patient at a 
hospital in New Delhi, India, has brought up worldwide public attention again (Bonomo, 2011; Rolain et al., 
2010). Although current reports indicate that NDM-1 does not hydrolyze monobactams, most of NDM-1-
carrying strains also express enzymes that could hydrolyze monobactams, making NDM-1-producers very 
difficult to control (Shakil et al., 2011). The rapid dissemination of NDM-1-producing gram-negative species 
also contributes to this major concern of public health. It has been reported in 50 countries across five continents, 
in the last 2 years (Bonomo, 2011; Rolain et al., 2010). NDM-1 is detected mainly in Enterobacteriaceae but 
occasionally in Acinetobacter baumannii, Stenotrophomonas maltophilia and P.aeruginosa ( Jovcic et al., 
2011).There is no evidence of the emergence of NDM-1-producing Enterobacteriaceae and P.aeruginosa in Iraq 
at this point. In the present study, we report the first isolation in Najaf of a NDM-1-producing P.aeruginosa. 
The aims of this study were to determine the existence of NDM β-lactamase producing P. aeruginosa isolates 
and their antibiotic susceptibility patterns in Najaf hospitals. 
Materials and Methods 
Bacterial isolates  
A total of 36 non-repetitively meropenem and/or imipenem resistant P. aeruginosa isolates were obtained from 
hospital environmental samples and patients visited/or admitted to different hospitals in the Najaf province 
included: Al-Sader Medical City, Al-Hakeem General Hospital, Al-Zahra'a Hospital for Childbirth and 
Children, over a period from February to October 2011. Isolates were acquired from specimens originated from 
instrument, floor, burn wound, ear and urinary tract. The isolates were identified by conventional biochemical 
methods and confirmed by using API 20E system.  
Antibiotic Susceptibility Assays: 
All isolates were tested in the Kirby Bauer method of disk diffusion to check their susceptibilities to norfloxacin 
(NX: 5 µg), ciprofloxacin (CIP: 5 µg), amikacin (AN: 30 µg), gentamicin (CN: 10 µg), tobramycin (TOB: 10 
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µg) aztreonam (ATM: 30 µg), meropenem (MEM: 10 µg), imipenem (IMP: 10 µg), cefepime (FEP: 30 µg), 
ceftriaxone (CRO: 30 µg), cefotaxime (CTX: 30 µg), ceftazidime (CAZ: 30 µg), ticarcillin- clavulanat (CTC: 
75/10 µg), piperacillin-tazobactam (PTZ: 110 µg), ticarcillin (TIC: 75 µg), piperacillin (PRL: 100 µg), 
carbenicillin (PY: 100 µg) (Himedia-India). Multidrug resistance (MDR) was defined as resistance to 3 or more 
classes of drugs that would otherwise serve as treatments for P. aeruginosa infection (Falagas et al., 2008). 
[7]Isolates found resistant to carbapenems (imipenem and meropenem) by disk diffusion test were re-checked in 
broth micro dilution assay (Clinical and Laboratory Standards Institute 2012).[8]. In this study, P. aeruginosa 
isolates were defined as resistant to carbapenems if MIC for imipenem and meropenem were ≥8µg/ml. The E. 
coli ATCC 25922 strain was adopted as the standard for quality control (Yong et al., 2002). 
Phenotypic screening for carbapenemases production:  
Double-disc synergy test (DDST): Screening for MBLs was performed using disks containing 1900 µg of 
EDTA plus 10 µg of imipenem disk were placed on the inoculated plates containing Muller Hinton agar. An 
increase of ≥ 17 mm in zone diameter in the presence 1900 µg of EDTA compared to imipenem alone indicated 
the presence of an MBL (Lee et al., 2003). 
Modified Hodge test (MHT): This test was carried out to detect carbapenemase using imipenem and meropenem 
as described by Clinical and Laboratory Standards Institute (2010). 
Carbapenemase bioassays: In order to determine whether resistance to imipenem and meropenem was likely 
caused by production of carbapenemase, a disk diffusion bioassay was performed on Mueller-Hinton agar with 
imipenem and meropenem disks as described by Walsh et al., (2002). 
PCR  amplification  
DNA was extracted from the isolates by boiling five colonies in 250 µl of sterile ultrapure water for 10 minutes, 
followed by cooling in ice for 10 minutes and centrifugation for 1 min at 14,000 rpm. Supernatants were 
conserved at -20°C until amplification (Hall &Barlow 2005). [13]. Amplification of blaNDM  gene was performed 
using primer pairs (F) 5'- ACCGCCTGGACCGATGACCA -3' and (R) 5'- GCCAAAGTTGGGCGCGGTTG -
3'. This set of primers gave rise to an amplicon of 264 bp. After initial denaturation for 2 min at 94°C, 35 cycles 
were performed (the conditions for each cycle were: 30 s at 95°C, 30 s at 58°C and 30 s at 72°C). The final cycle 
was followed by 72°C incubation for 10 min. The PCR product was electrophoresed on 1.5% agarose gel and 
following ethidium bromide staining was viewed under UV light (Zarfel et al., 2011). 
Results 
Meropenem and /or imipenem resistant isolates were collected as part of the first national study on the 
distribution and evolution of carbapenem resistance P. aeruginosa in Najaf hospitals. The frequency of the 
isolates and their sites of isolation are listed in table (1). High percentage of resistant carbapeneme isolates 
19/36(52.7%) were received from burin wound samples in compared with others. Majority of the isolates were 
obtained from Al-Sader Medical City (80.6%) followed by Al-Hakeem General Hospital (11.1%),  since only a 
minority of these isolates were from Al-Zahra'a Hospital for Childbirth and Children (8.3%). 
Present results revealed that a total of 10 different antibiotic resistance phenotypes were seen among the 
carbapenem-resistant isolates, although some of these were minor variants. Three phenotypes were predominant, 
as follows: phenotype class I, resistant to all antibiotics (12 isolates, 33.3%), phenotype class II, susceptible only 
to imipenem (11 isolates, 30.6%); phenotype class III, susceptible to imipenem and amikacin but resistant to all 
other antimicrobials tested (5 isolates 13.9%). The remaining 8 phenotypes accounted for 19.4% of the 
meropenem-resistant isolates. 
Antibiotic susceptibility pattern revealed that 4(11.1%) isolates were resistant to at least three classes of 
antibiotics, hence they were considered to be MDR. The current study also reported that  20 (55.5%) and 
12(33.3%) of carbapenem resistance P. aeruginosa isolates were extensive drug resistant (XDR) and pandrug 
resistant (PDR) isolates respectively (Table 2). The MIC of imipenem showed a varied range from ≥4 to ≥128 
µg/ml. Twenty eight (77.8%) isolates showed imipenem resistance (8-128) µg/ml. In particular, none of the 
isolates showed an MIC value >4 µg/ml for imipenem. Similarly, MIC of meropenem ≥8 µg/ml for 34(94.4%) 
and 2 isolates were  ≥256 µg/ml. 
The phenotypic technique for detecting carbapenemase activity. Among over all carbapenem resistant isolates 
(36), table (4) shows only 28 (77.8%) and 14 (38.9%) were positive according to imipenem-meropenem-EDTA 
disk synergy test (Figure 1) and modified Hodge test respectively. EDTA-imipenem microbiological assay was 
document 28 (77.8%) bacterial extract with and without ZnSO4 indicated the presence of carbapenemase 
activity. Moreover, indicator strain growth was inhibited around the same 28 (77.8%) bacterial extract 
supplemented with EDTA confirmed the presence of MBLs (Figure 2). 
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The PCR amplification of NDM gene confirmed that 2 (5.6%) isolates harbored blaNDM gene (Pa9 and Pa22) 
Figure (3). All NDM- producing isolates exhibited high antibiotic resistance and had a XDR phenotype (Table 
2). 
Discussion  
P. aeruginosa classically considered as one of the leading Gram-negative pathogen that causes nosocomial 
infections worldwide (Meenakumari et al., 2011). It is one of the most important bacterial pathogen seriously 
contributing to the problem of hospital infections (Fonseca et al., 2007), so has received most attention in Najaf 
hospitals. 
In the present study, a high rate of resistance among isolates recovered from clinical and hospital environments 
from three hospitals in Najaf city was documented. The largest carbapenem-resistant isolates taken hold of Al-
Sader Medical City afterwards Al-Hakeem General Hospital and in the wake of little from Al-Zahra'a Hospital 
for Childbirth and Children. Carbapenems are potent agents against multiresistant P. aeruginosa, in spite of the 
slightly use of carbapenem therapy in these hospitals, but survey data show emerging resistance in P. aeruginosa 
isolates. 
The emergence of carbapenem resistant by acquired carbapenemase including MBLs among P. aeruginosa 
represents an epidemiological risk for at least two reasons. Firstly, carbapenemase confer resistance not only to 
carbapenems but to virtually all β-lactams and are frequently associated with resistance to numerous 
aminoglycosides; and secondly, genes encoding for carbapenemase enzymes are most commonly carried on 
mobile genetic elements (integrons, plasmids, transposons) that can spread horizontally among unrelated strains 
(Walsh, 2005; Hammami et al., 2010). 
The rate of resistance to β-lactams was high in this study. It seems that other mechanisms such as decreased 
permeability, over expression of efflux pump, production of carbapenemases probably are involved in resistance 
to β-lactams. Understanding the underlying genetic mechanisms responsible for the acquisition and spread of 
this unique β-lactamase mediated antibiotic resistance mechanism could eventually facilitate the development of 
effective prevention and control strategies and thereby allowing more effective drug usage and treatment of 
disease, and reducing resistance development (Yong et al., 2002).This may confer with high incidence of MDR, 
XDR and PDR observed among P. aeruginosa isolates underlines the strict consideration in antibiotics use at 
Najaf hospitals.  
The production of MBL is the most common mechanism for carbapenem resistance in Enterobacteriaceae and 
P. aeruginosa isolates (Lledo et al., 2009; Munoz-Price &Quinn 2009). Present study revealed that 14 isolates 
were modified Hodge’s test positive which optimistically indicate that they may possess the carbapenemase 
gene, which mediated the carbapenem resistance. MBLs have been identified from clinical isolates worldwide 
with increasing frequency over the past few years and strains producing these enzymes have been responsible for 
prolonged nosocomial outbreaks that were accompanied by serious infections (Hemalatha et al., 2005; Marra et 
al., 2006).  
The resistant isolates were tested by the imipenem-meropenem-EDTA disk synergy test, 77.8% were found to be 
MBL producers phenotypically. Several studies reported that imipenem-EDTA combination was most sensitive 
in detection of MBL in P. aeruginosa (Queenan &Bush 2007).  A high proportion of isolates produced MBL 
was found in Najaf hospitals. Present study revealed that this test may be useful in screening for MBL. This 
report was in concordance with the results of two Indian studies on the detection of MBL by DDST reported that 
70% and 75% were MBL positive (Uma et al., 2009; Gupta& Chander 2006), respectively. In this study, EDTA-
imipenem microbiological assay was used in order to detect metalloenzymes in all isolates with cellular extracts. 
The positive isolates suggesting the presence of MBLs. This result displayed a performance comparable to that 
of imipenem-meropenem-EDTA disk synergy test, concerning the high sensitivity of these methods for the 
detection of MBL producers.  
The present study report here the first two cases of infections due to NDM-1-producing P. aeruginosa in Iraq. 
The gene encoding NDM-1 is located in a very mobile genetic element, resulting in rapid spread across the 
species and countries (Yong et al., 2009; Cholley et al., 2011). However, the blaNDM-1 gene positive 
Enterobacteriaceae has spread from India, Pakistan and Bangladesh to UK, US, France (Flateau et al.,2012), 
Kenya, Japan, Canada, Belgium, the Netherlands, Serbia (Leverstein-van et al.,2010), Taiwan (Wu et al., 2010), 
Singapore, Sultanate of Oman (Poirel et al., 2011a), Australia (Poirel et al.,2010) and Iraq (Poirel et al., 2011b). 
A substantial number of infected/colonized patients have been part of the so-called “medical tourism.” The 
antibiotic resistant pattern revealed that isolates harbored blaNDM were XDR phenotype. NDM-1 producing 
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bacteria are usually extensivedrug to antibiotics because blaNDM-1 encoding plasmids co-harbor 
multipleresistance determinants. Moreover, P. aeruginosa shows a high level of intrinsic resistance to 
antimicrobial agents. Its ability to acquire and combine different resistance determinants represents a major 
threat, compromising therapeutic options (Moriyama et al., 2010; Prevotat et al., 2010). 
Conclusion 
In conclusion, the detection of NDM-1-positive P. aeruginosa isolates in this study indicates immediate 
importance of strengthening surveillance to prevent the nosocomial infection and dissemination of NDM-1 in 
Najaf. 
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Table 1: Sample demographics and antibiotics susceptibilities of carbapenem-resistant P. aeruginosa isolates 
 
1(
   *Sh, Al-Sader Medical City; Hh, Al-Hakeem General Hospital; Al-Zahra'a Hospital for Childbirth and 
Children 
2(
 **BW, Burin wound; Ur, Urine; Ea, Ear; IN, Instrument; FL, Floor. 
3(
 I, II,III, phenotype class 1,2 and 3. 
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18-I R R R R R R R  R R R R R R R R R R R Ea Sh Pa29 
18-I R R R R R R R  R R R R R R R R R R R UR  H* Pa30 
17-II R R R R R R S R R R R R R R R R R R UR  Sh Pa31 
18-I R R R R R R R R R R R R R R R R R R BW Sh Pa32 
18-I R R R R  R R R  R R R R R R R R R R R BW Sh Pa33 
18-I R R R R R R R R R R R R R R R R R R FL Sh Pa34 
17-II R R R R R R S R R R R R R R R R R R FL Zh Pa35 
16-III R R R S R R S R R R R R R R R R R R BW Sh Pa36 
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Table 2: Multidrug resistance (MDR), extensive drug resistance (XDR) and pandrug resistance (PDR) of 
carbapenem-resistant P.aeruginosa isolates (n=36). 
Type of resistance Isolate symbol No. of antibiotics classes(n= 7) 
MDR (n=4, 11.1%) Pa20, Pa27  3 
Pa1, Pa2 4 
XDR (n=20, 55.5%) 
Pa3, Pa13 , Pa16, Pa17, , Pa21, 
Pa26, Pa28, Pa35, Pa36 5 
 Pa4, Pa5, Pa6, Pa8, Pa 9, Pa10, 
 Pa12, Pa14, Pa 19, Pa22, Pa31, 6 
PDR (n=12, 33.3%) Pa7, Pa 11, Pa15, Pa18, Pa23, Pa24, Pa25, Pa29, Pa30, Pa32, Pa33, Pa34 7 
 
Table 3: MIC values (µg/ml) and susceptibility of P. aeruginosa isolates (n=36) for carbapenems according to 
(CLSI, 2012) 
 
Table 4: Phenotypic screening for carbapenemase production in 36 P. aeruginosa isolates 
 
Test  Positive Negative 
imipenem-meropenem -EDTA disk synergy test 28 (77.8) 8 (22.2) 
modified Hodge test 14 (38.9) 22 (61.1) 
EDTA-imipenem  microbiological assay 28 (77.8) 8 (22.2) 
 
 
 
Figure 1: Performances of imipenem-meropenem-EDTA disk synergy test using disks of carbapenems 
(imipenem, IMP and meropenem, MRP) and disk of EDTA (1.900 µg). Panel show results for P. aeruginosa 
isolate Pa34. Carbapenems disks and an EDTA disk produced large synergistic inhibition zones for isolate (top). 
An IMP disk and a MRP disk failed to produce inhibition zones (bottom). 
 
Meropenem  Imipenem  Status  
No.(%)  of isolate Range (µg/ml) No.(%) of isolate  Range (µg/ml) 
36(100%) 8-256 28(77.8%) 8-128 Resistant 
0(0.0%)  - 8(22.2%) 4 Intermediate 
0(0.0%)  - 0(0.0%)  - Susceptible 
EDTA 
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Figure 2: Detection of metallo-β-lactamases in P. aeruginosa isolate Pa34 by EDTA-imipenem microbiological 
assay. The presence of enzymes hydrolyzing imipenem (IPM) in bacterial extracts was tested by the growth of 
the E. coli ATCC 25922-indicator strain. The different disks were as follows: S, containing bacterial extract; 
S/Zn, containing bacterial extract supplemented with ZnSO4; S/E, containing bacterial extract supplemented with 
EDTA; B, containing buffer. The growth of E. coli cells around the bacterial extract with and without ZnSO4 
indicated the presence of imipenemase activity. MBLs differentiated from nonmetalloenzymes by indicator 
strain growth inhibition around a bacterial extract supplemented with EDTA. 
 
 
Figure 3: Ethidium bromide-stained agarose gel of PCR amplified products from extracted DNA of P. 
aeruginosa amplified with blaNDM gene primers (forward and reverse). The electrophoresis performed at 60 volt 
for 2 hr. Lane (L), DNA molecular size marker (l500-bp ladder), Lanes (9 and 22) of P. aeruginosa isolates 
show positive results with blaNDM (264 bp). 
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